22KIT
becomes available in the UK.
www.roche.co.uk
Trinity Biotech
Trinity Biotech is a commercial-stage
biotechnology company focused
on human diagnostics and diabetes
management solutions, including
wearable biosensors, today unveiled
its new flagship product, CGM+.
This is a next-generation wearable
biosensor platform now in the later
stages of device development, CGM+
is Trinity's new AI-native continuous
glucose monitoring (CGM) system,
combining multi-sensor data and
real-time analytics to meet the
evolving demands of AI-powered
healthcare and wellness.
Unlike traditional CGMs focused
solely on glucose monitoring, CGM+
integrates an ultra-thin minimally
invasive electrochemical glucose
sensor with continuous monitoring
of heart activity, body temperature
and physical activity-all within
a single, sleek and user-friendly
modular wearable device. This
multimodal data stream is being
optimized for real-time AI analysis,
to enable a deeper, more contextual
understanding of metabolic and
physiological health. Trinity Biotech
has identified these expanded data
points as critical to gain insights into
essential metabolic factors, including
sleep, stress, and physical activity.
Trinity Biotech's vision is to combine
medical-grade monitoring and
consumer wellness insights, through
the CGM+ platform, positioning
Trinity Biotech at the forefront
of a new category of intelligent
wearables.
Trinity Biotech's proprietary
needle-free glucose sensor
technology facilitates the collection
of expanded data points from a
single modular wearable device. The
Company's latest innovative design
utilises this technology to provide
a solution that not only reduces the
number of disposable components
and waste, but also significantly
Trinity Biotech's CGM+ wearable
biosensor designed to seamlessly
integrate glucose, cardiovascular,
temperature, and activity
monitoring in one modular device.
lowers the cost of care compared to
current leading market products. The
plan is to get this through FDA and
go public in 2028.
"CGM+ is not just a device
- it's a proprietary data engine
we are building for the AI health
ecosystem," said John Gillard, CEO
of Trinity Biotech. "We believe this
technology can power the next wave
of personalized, predictive, and
preventative care while opening up
entirely new commercial pathways
for Trinity Biotech, from device
sales to AI-driven data services. It
will also position us to compete well
beyond traditional diagnostics, at
the intersection of chronic disease
management, digital health and
consumer wellness."
trinitybiotech.com
Twiist pump
The Twiist now officially available
in select areas in the U.S. The
automated insulin delivery system
uses Tidepool's Loop algorithm,
which is embedded in a circular,
tubed pump. The system's pump
uses a novel way to measure insulin
with sound waves - an approach that
may allow for more accurate dosing.
It's also the first FDA-approved
AID system that can be directly
controlled by an Apple Watch.
Roughly 4,000 people on a
waiting list will be prioritized during
a regional rollout, with nationwide
availability expected by year's end.
The Twiist AID System is now
compatible‡ with the Freestyle Libre
3 Plus sensor, currently the world's
smallest, most discreet 15-day sensor,
giving you accurate, minute-byminute readings,
with no overpatch
needed. Together, your Twiist AID
System and the Freestyle Libre 3 Plus
sensor simplify your routine with a
single-app set up, no sensor coding
required, and personalized diabetes
support right when you need it.
www.sequelmedtech.com